

ABSTRACT GUIDELINES

- Abstracts should represent the original work
- Abstracts should be submitted using the Abstract Submission Form available at: <https://clinicaltrialsalliance.org.au/events-forums/acta-asm-2021/>
- Abstracts are limited to 300 words, excluding author(s) names, affiliations, organisations and references
- Please only use standard abbreviations or define them in full
- Results must be included. Abstracts with “results will be presented” statements will not be considered
- The presenting author must be listed as an author on the abstract during submission. If for any reason the nominated presenting author cannot submit the final poster a replacement author can give the presentation, but the replacement presenter must have been listed as an author during the original abstract submission. If no named authors are available, the abstract must be withdrawn
- Please nominate a program stream most relevant for your abstract during submission. The streams are:
 - Stream 1: Translation of clinical registry findings into practice
 - Stream 2: Capacity building to optimise trial design, conduct and impact
 - Stream 3: Facilitating efficient and cost-effective recruitment and completion of clinical trials
 - Stream 4: Accelerating Australian discovery and innovation through trials and well-phenotype cohorts
 - Stream 5: Australia as the “go to” partner for global and industry supported trials.
- Please send in a brief biography together with the abstract (*This biography should be no more than 100 words and should describe the author’s professional credentials, background, experience, and research interests/initiatives*)
- Documents that do not conform to the guidelines will be asked to revise
- Documents received after the given deadline, due to any reason, will not be accepted unless the deadline is extended.

ABSTRACT SUBMISSION

- Abstracts should be submitted using the Abstract Submission Form available at: <https://clinicaltrialsalliance.org.au/events-forums/acta-asm-2021/>
- Submit your abstract according to the above guidelines to events@clinicaltrialsalliance.org.au by **5pm AEST on Monday 20 September 2021**
- After submission, you will receive an acknowledgement email of receipt within three working days.

NOTE: Please be sure to submit well before the submission deadline to be eligible for Early Bird rates to reserve your seats for the meeting.

EMERGING LEADER INVESTIGATOR AWARD

- An emerging is considered as having up to 12 years post-doctoral experience
- The applicant must be the first author, and presenting author, of the submitted abstract
- The applicant must be able to present their abstract 'live' at the virtual ACTA ASM between 2.30-3.15pm AEST on Thursday 11 November 2021. If a candidate is unable to be present at this time, then the award is forfeited.

ABOUT THE REVIEW PROCESS

- The ACTA ASM Convener serves as the head of the Organising Committee and will make the final decision on which abstracts are accepted
- Abstracts will be reviewed against the following criteria:
 - Completed rather than future work (i.e. final results)
 - Original data of high quality

- An analysis that extends existing knowledge
- Diversity and consumer involvement
- Clarity of methodology, analysis and presentation of results
- Specific rather than general findings.
- Results of the abstract review will be sent to the author by 15 October 2021
- Acceptance or rejections of the abstract will be sent to you with reviewer comments
- If a revision is required, the revised abstract must be sent back within one week or request
- If your abstract is accepted, you will be invited to register for the ACTA ASM. **NOTE:** Failure to register will result in withdrawal of the abstract.

PRESENTATIONS

Accepted abstract authors for Stream 1 will be invited to submit a digital poster (with optional pre-recorded commentary) for the poster session.

Accepted abstract authors for Streams 2-5 will be invited to submit a digital poster (with optional pre-recorded commentary) for the poster session.

Selected abstract authors may also be invited to provide a pre-recorded oral presentation as part of the main program.

IMPORTANT INFORMATION FOR AUTHORS

- If you submit a successful abstract, the author must register to attend the ACTA ASM by **29 October 2021**
- If the co-authors would like to attend the meeting, their registration and payment are required to be made independently
- All accepted abstracts will be made available to ACTA ASM delegates as a digital poster
- Authors are responsible for proof reading and submitting an abstract or poster without errors, as they will be reproduced in the format they were submitted
- The corresponding author is responsible for the abstract content. This author is the contact person for submission or communication purposes and is also responsible for disseminating information related to the co-authors
- All enquiries regarding abstract submissions should be emailed to events@clinicaltrialsalliance.org.au